# breast cancer - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 3
- Task type: PROGNOSIS
- Tissue / sample source: breast tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: 2eef237c25053f55d87c73e963368cae88b5c698447f11e7e98ebc594d62e5bb
- Response HTTP status: 200
- Prompt tokens: 30814
- Completion tokens: 12389
- Reasoning tokens: 0
- Total tokens: 43203
- API requests reported: 2
- Elapsed seconds: 271.996
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 685.605
- Question handoff seconds: 699.996
- Final benchmark system: E2seq; file rank 2/5; original repeat 3; model vendor: DeepSeek

---
# Multidimensional Interpretation of Prognostic Transcriptomic Results in Breast Cancer

## 1. Overall Biological Interpretation

This prognostic analysis of breast tumor tissue (endpoint: overall survival, OS) identifies 100 unique genes with highly significant survival associations (all FDR ≤ 1.74×10⁻⁶; 52 risk-associated with HR > 1, 48 protective-associated with HR < 1). The effect sizes are modest (HR range approximately 0.79–1.26), but the statistical significance is extreme throughout, indicating a robust, internally consistent signal rather than a sparse or noisy result.

The dominant biological pattern is a **proliferative/cell-cycle risk program**: a large cluster of risk-associated genes (HR > 1) encodes core cell-cycle regulators, mitotic spindle components, and DNA replication/repair factors (e.g., CDC20, AURKA, TPX2, KIF20A, KIF4A, CDCA5, UBE2C, UBE2S, PRC1, NUSAP1, CKAP2L, CCNE2, PTTG1, TK1, FEN1, TIMELESS). This is counterbalanced by a **protective program enriched for immune-related and stromal/differentiation markers** (HR < 1): immunoglobulin/J-chain components (JCHAIN), antigen-presentation and immune receptors (CD1C, CD1E, FCER1A, KLRB1, FLT3, IL27RA), and extracellular-matrix/differentiation genes (COL17A1, LAMA2, LAMA2-related, OGN, OMD, MFAP4, RELN, PDGFRA, IGF1). A second risk-associated theme involves **metabolic and stress-response genes** (CPT1A, GPI, GSK3B, TRIB3, GPRC5A, STIP1, LARP1, YTHDF1), suggesting that proliferation is coupled with metabolic reprogramming and translational/epigenetic regulation.

The overall picture is consistent with the established paradigm in breast cancer that high proliferative capacity and cell-cycle deregulation portend worse survival, whereas immune infiltration and certain differentiation/stromal programs associate with better outcomes. However, the protective immune signal must be interpreted cautiously because immune-cell content in bulk tumor tissue reflects composition as much as intrinsic tumor biology.

---

## 2. Core Biological Programs

### Program 1: Cell-Cycle Progression and Mitotic Machinery
- **Direction**: Risk-associated (HR > 1)
- **Supporting genes**: CDC20 (HR=1.191), AURKA (HR=1.189), TPX2 (HR=1.202), KIF20A (HR=1.218), KIF4A (HR=1.199), CDCA5 (HR=1.218), PRC1 (HR=1.186), NUSAP1 (HR=1.194), CKAP2L (HR=1.191), PTTG1 (HR=1.197), UBE2C (HR=1.210), UBE2S (HR=1.184), CCNE2 (HR=1.186), ZWINT (HR=1.191), CENPO (HR=1.189), PKMYT1 (HR=1.244), RACGAP1 (HR=1.224)
- **Standard pathway**: KEGG "Cell cycle" (hsa04110) and Reactome "Mitotic prometaphase" / "Resolution of sister chromatid cohesion"
- **Rationale**: These genes collectively encode the machinery of mitotic entry (AURKA–TPX2 complex), spindle assembly and chromosome segregation (KIF20A, KIF4A, PRC1, NUSAP1, RACGAP1, ZWINT, CENPO), the anaphase-promoting complex/cyclosome (APC/C) targets and regulators (CDC20, UBE2C, UBE2S, PTTG1), and S-phase/G2 entry (CCNE2, CDCA5, PKMYT1). The consistency of direction across >15 independent genes makes this the strongest and most coherent risk program.
- **Evidence strength**: Strong. Direct input statistics (all FDR < 1.2×10⁻⁶) plus pathway co-membership in KEGG Cell cycle and Reactome mitotic pathways. STRING network evidence shows connectivity among AURKA, TPX2, KIF4A, NUSAP1, PRC1 (spindle module) and among CDC20, UBE2C, UBE2S, PTTG1 (APC/C module). Limitation: these are pathway co-membership and interaction-database records, not independent cohort statistics.

### Program 2: Immune Response and Antigen Presentation
- **Direction**: Protective-associated (HR < 1)
- **Supporting genes**: JCHAIN (HR=0.803), CD1C (HR=0.814), CD1E (HR=0.824), FCER1A (HR=0.793), KLRB1 (HR=0.822), FLT3 (HR=0.817), IL27RA (HR=0.825), STAT5A (HR=0.806), STAT5B (HR=0.837), PPIL3 (HR=0.810)
- **Standard pathway**: Reactome "Antigen processing and presentation" / "Adaptive immune system" (for CD1 family, JCHAIN); GO "immune response"
- **Rationale**: JCHAIN encodes the joining chain of IgA/IgM, marking plasma cells and B-lineage infiltration; CD1C and CD1E encode lipid-antigen-presenting molecules expressed on dendritic cells; KLRB1 marks innate-like T/NK subsets; FLT3 is expressed on dendritic-cell progenitors; IL27RA is an immune-regulatory cytokine receptor. The coordinated protective direction suggests that tumor immune infiltration—particularly dendritic-cell and B/plasma-cell components—associates with better OS.
- **Evidence strength**: Moderate-to-strong direct statistics (all FDR < 1.3×10⁻⁶). However, the interpretation is complicated by the fact that in bulk tumor RNA, these genes largely reflect immune-cell content rather than tumor-cell-intrinsic expression. This is a composition signal as much as a tumor-intrinsic program.

### Program 3: Proliferation-Coupled DNA Replication and Repair
- **Direction**: Risk-associated (HR > 1)
- **Supporting genes**: TK1 (HR=1.210), FEN1 (HR=1.189), TIMELESS (HR=1.196), RPA2 (HR=0.832, protective), UHRF1 (HR=1.209), DDX41 (HR=1.191), YTHDF1 (HR=1.192)
- **Standard pathway**: Reactome "DNA replication" / "DNA repair"; KEGG "Pyrimidine metabolism" (TK1)
- **Rationale**: TK1 (thymidine kinase) and FEN1 (flap endonuclease) are direct S-phase replication enzymes; TIMELESS is a replication-fork protection factor; UHRF1 couples DNA replication to epigenetic maintenance (DNMT1 recruitment); YTHDF1 is an m⁶A reader linking mRNA stability/translation to proliferation. Most of these are risk-associated, consistent with active DNA synthesis driving worse survival. RPA2 is protective in this dataset (HR=0.832), which is directionally discordant with the replication program and warrants caution—single-gene exceptions within a broad program are expected but should be noted.
- **Evidence strength**: Moderate. Multiple independent genes with strong direct statistics, but the program overlaps heavily with Program 1 (both reflect proliferation) and thus is not fully independent.

### Program 4: Metabolic Reprogramming and Stress Adaptation
- **Direction**: Risk-associated (HR > 1)
- **Supporting genes**: CPT1A (HR=1.196), GPI (HR=1.192), GSK3B (HR=1.227), TRIB3 (HR=1.191), GPRC5A (HR=1.202), STIP1 (HR=1.237), LARP1 (HR=1.261), ALG3 (HR=1.187), HACD3 (HR=1.197)
- **Standard pathway**: KEGG "Glycolysis / Gluconeogenesis" (GPI); Reactome "Fatty acid metabolism" (CPT1A); Reactome "mTOR signalling" (LARP1 is an mTOR-regulated 5'TOP mRNA-binding protein)
- **Rationale**: CPT1A is the rate-limiting enzyme for mitochondrial fatty-acid oxidation; GPI is a glycolytic enzyme; GSK3B is a pleiotropic kinase integrating Wnt, insulin, and cell-cycle signaling; TRIB3 is a stress-induced pseudokinase; STIP1 is an HSP70/HSP90 co-chaperone supporting client-protein stability under proteotoxic stress; LARP1 regulates translation of ribosomal proteins downstream of mTOR. The risk direction of these metabolic and stress-adaptation genes suggests that tumors with active metabolic reprogramming and proteostatic adaptation have worse OS.
- **Evidence strength**: Moderate. The genes are individually strongly significant but are biologically heterogeneous (lipid oxidation, glycolysis, chaperone function, translation). This is the least "single-mechanism" program and may reflect several parallel survival-promoting adaptations rather than one coherent pathway.

### Program 5: Extracellular Matrix, Stroma, and Differentiation
- **Direction**: Protective-associated (HR < 1)
- **Supporting genes**: COL17A1 (HR=0.798), LAMA2 (HR=0.830), OGN (HR=0.807), OMD (HR=0.829), MFAP4 (HR=0.834), RELN (HR=0.796), ADAMTS8 (HR=0.793), DST (HR=0.807), PCDH18 (HR=0.825), CLDN11 (HR=0.819), TP63 (HR=0.810), IGF1 (HR=0.803), PDGFRA (HR=0.838), LEPR (HR=0.821)
- **Standard pathway**: GO "extracellular matrix organization"; Reactome "ECM proteoglycans" / "Laminin interactions"
- **Rationale**: These genes encode basement-membrane components (COL17A1, LAMA2), small leucine-rich proteoglycans (OGN, OMD), matricellular proteins (MFAP4), and adhesion/signaling molecules (RELN, PCDH18, CLDN11, DST). TP63 is a basal/epithelial stem-cell transcription factor. The protective direction of this ECM/differentiation cluster is notable because in some breast cancer contexts, certain matrix programs associate with aggressive biology—suggesting that the specific composition of this protective ECM signal (possibly reflecting normal-adjacent tissue or differentiated luminal/basal cells) differs from the reactive desmoplastic stroma that typically promotes invasion.
- **Evidence strength**: Moderate. Strong direct statistics, but the interpretation is complicated by the fact that in bulk tumor tissue, these ECM genes may reflect stromal-cell content, normal-adjacent contamination, or tumor-cell-intrinsic differentiation status. The direction (protective) is internally consistent and biologically plausible but requires cell-type-resolved validation.

---

## 3. Key Genes and Interaction Modules

### Module 1: AURKA–TPX2–KIF4A–NUSAP1–PRC1 (Mitotic Spindle Module)
- **Statistics**: AURKA HR=1.189, TPX2 HR=1.202, KIF4A HR=1.199, NUSAP1 HR=1.194, PRC1 HR=1.186 (all FDR < 1.3×10⁻⁶)
- **Role**: Core mitotic spindle assembly and chromosome segregation machinery.
- **Relationships**: Direct physical interaction (AURKA–TPX2 is a well-established kinase–activator complex; TPX2 directs AURKA to spindle poles and activates it). KIF4A, NUSAP1, and PRC1 are spindle-associated proteins that function in the same mitotic process; STRING records show network connectivity, but these are pathway co-membership/co-function relationships rather than all being direct physical partners of AURKA.
- **Attention rationale**: This module is the most coherent risk-associated unit and is a well-validated proliferation axis across cancers.

### Module 2: CDC20–UBE2C–UBE2S–PTTG1 (APC/C Module)
- **Statistics**: CDC20 HR=1.191, UBE2C HR=1.210, UBE2S HR=1.184, PTTG1 HR=1.197 (all FDR < 1.2×10⁻⁶)
- **Role**: APC/C activation (CDC20), ubiquitin conjugation (UBE2C, UBE2S), and securing/securin regulation (PTTG1) to drive mitotic exit and anaphase.
- **Relationships**: Direct physical/functional interaction within the APC/C pathway: CDC20 is the APC/C co-activator; UBE2C and UBE2S are the E2 enzymes that ubiquitinate APC/C substrates; PTTG1 (securin) is an APC/C substrate whose degradation is required for sister-chromatid separation. STRING records confirm connectivity; the biochemical pathway relationship is well established.
- **Attention rationale**: This module is druggable (APC/C inhibitors and CDK1–APC/C interplay) and represents a convergent risk hub.

### Module 3: STAT5A/STAT5B–FLT3–LEPR–IL27RA (JAK/STAT and Immune Signaling)
- **Statistics**: STAT5A HR=0.806, STAT5B HR=0.837, FLT3 HR=0.817, LEPR HR=0.821, IL27RA HR=0.825 (all protective)
- **Role**: Cytokine receptor signaling that supports immune-cell differentiation and function.
- **Relationships**: Regulatory signaling pathway: FLT3 ligand receptor and LEPR (leptin receptor) activate JAK–STAT5 signaling; STAT5A/STAT5B are downstream transcription factors; IL27RA is an immune-regulatory receptor. STRING records show connectivity among FLT3, LEPR, STAT5A, STAT5B. These are pathway co-membership/regulatory relationships, not all direct physical interactions.
- **Attention rationale**: The uniformly protective direction of this immune-signaling module contrasts with the risk-associated proliferation modules and suggests that STAT5-dependent immune programs may contribute to favorable prognosis.

### Module 4: GSK3B–WNT7B–CTNNB1 (Wnt/β-Catenin Signaling Node)
- **Statistics**: GSK3B HR=1.227 (risk), WNT7B HR=1.183 (risk)
- **Role**: GSK3B is a core component of the β-catenin destruction complex (with AXIN1, APC, CTNNB1 per STRING records) and also regulates cell-cycle and metabolism. WNT7B is a Wnt ligand that can activate β-catenin signaling.
- **Relationships**: Direct physical interaction—GSK3B phosphorylates β-catenin in the destruction complex (STRING confidence 0.999 with CTNNB1, AXIN1, APC). WNT7B acts upstream as a ligand, a regulatory/paracrine relationship. The risk direction of both GSK3B and WNT7B is notable because GSK3B is often considered tumor-suppressive in Wnt signaling; its risk association here may reflect its broader kinase roles (cell cycle, metabolism, NF-κB) rather than Wnt suppression.
- **Attention rationale**: GSK3B is the third-strongest risk gene by HR (1.227) and is a tractable drug target; its role in breast cancer prognosis is context-dependent and warrants mechanistic dissection.

### Module 5: YTHDF1–LARP1–STIP1 (Translation and Proteostasis)
- **Statistics**: YTHDF1 HR=1.192, LARP1 HR=1.261 (highest HR in the cohort), STIP1 HR=1.237 (risk)
- **Role**: YTHDF1 is an m⁶A RNA reader promoting translation of target mRNAs; LARP1 regulates 5'TOP mRNA translation downstream of mTOR; STIP1 is an HSP70/HSP90 co-chaperone.
- **Relationships**: Co-functional/regulatory, not direct physical interaction among all three. YTHDF1 and LARP1 both regulate translation but through distinct mechanisms; STIP1 supports protein folding of client proteins. STRING records do not indicate direct physical interaction among these three.
- **Attention rationale**: These are among the strongest risk-associated genes (LARP1 HR=1.261, STIP1 HR=1.237) and represent an underexplored axis linking translation control and proteostasis to poor survival.

### Module 6: PKMYT1–CCNE2–CDCA5 (G2/M and S/G2 Transition)
- **Statistics**: PKMYT1 HR=1.244, CCNE2 HR=1.186, CDCA5 HR=1.218 (risk)
- **Role**: PKMYT1 inhibits CDK1 (G2/M gate); CCNE2 promotes S-phase entry; CDCA5 (Sororin) regulates sister-chromatid cohesion.
- **Relationships**: Pathway co-membership in cell-cycle control; PKMYT1 is a kinase that phosphorylates CDK1, a regulatory interaction; CCNE2 activates CDK2, a regulatory interaction. No direct physical interaction among all three.
- **Attention rationale**: PKMYT1 is the second-strongest risk gene by HR and is an emerging therapeutic target in cell-cycle-addicted tumors.

---

## 4. Validation Priorities

### Priority 1: Cell-Cycle/Mitotic Program as a Therapeutic Target
- **Classification**: Therapeutic target
- **Why**: The mitotic module (AURKA, TPX2, CDC20, UBE2C, PKMYT1) is the most coherent risk program with multiple independent genes, strong statistics, and established druggability (AURKA inhibitors, CDK1 modulators).
- **Dataset evidence**: 15+ risk-associated genes with FDR < 1.2×10⁻⁶.
- **External evidence**: AURKA and TPX2 are well-validated proliferation markers across cancers; AURKA inhibitors exist (e.g., alisertib), and CDC20/APC/C is an active drug-discovery area. However, prior clinical trials of AURKA inhibitors in breast cancer have shown limited efficacy, so drug presence does not imply effectiveness.
- **Next step**: Functional perturbation (siRNA/CRISPR or small-molecule inhibition) of AURKA, TPX2, or CDC20 in breast cancer cell lines with high expression of this module; assess proliferation, mitotic index, and apoptosis. Test whether module expression predicts sensitivity to AURKA inhibitors in patient-derived models.
- **Conclusion status**: Supported hypothesis (mechanism well established in cancer biology; therapeutic efficacy in this specific context is exploratory).

### Priority 2: Immune-Cell Composition as a Protective Biomarker
- **Classification**: Confounding or composition check
- **Why**: The protective immune genes (JCHAIN, CD1C, CD1E, KLRB1, FLT3) likely reflect immune-cell infiltration in bulk tumor tissue. Distinguishing tumor-cell-intrinsic from microenvironment effects is essential before any biomarker claim.
- **Dataset evidence**: 10+ protective immune genes with FDR < 1.3×10⁻⁶.
- **External evidence**: Immune infiltration (particularly T cells, dendritic cells, plasma cells) is associated with better prognosis in multiple breast cancer cohorts; this is well established (e.g., tumor-infiltrating lymphocytes in triple-negative breast cancer).
- **Next step**: Deconvolution of bulk RNA-seq (CIBERSORTx, xCell) or single-cell/spatial transcriptomics to determine which cell types express the protective genes; correlate with immune-cell abundance and survival in an independent cohort.
- **Conclusion status**: Supported hypothesis for immune-infiltration association; tumor-cell-intrinsic contribution is exploratory.

### Priority 3: LARP1–YTHDF1 Translation Axis as a Mechanistic Hypothesis
- **Classification**: Mechanistic hypothesis
- **Why**: LARP1 has the highest HR (1.261) and YTHDF1 is a strong risk gene (1.192); both regulate translation but through distinct mechanisms (mTOR-dependent 5'TOP mRNA regulation vs. m⁶A-dependent translation). Their co-occurrence suggests a convergent translation-addiction program.
- **Dataset evidence**: Both genes risk-associated with FDR < 4.7×10⁻⁷.
- **External evidence**: YTHDF1 is implicated in tumor proliferation in several cancers; LARP1 is an mTORC1 downstream effector. However, direct evidence in breast cancer prognosis is limited.
- **Next step**: Test whether LARP1/YTHDF1 knockdown reduces proliferation or translation of shared target mRNAs in breast cancer models; assess whether their expression correlates with mTOR pathway activation.
- **Conclusion status**: Exploratory hypothesis.

### Priority 4: GSK3B Context-Dependent Role in Breast Cancer Prognosis
- **Classification**: Mechanistic hypothesis
- **Why**: GSK3B is a strong risk gene (HR=1.227) but is canonically tumor-suppressive in Wnt signaling. Resolving this apparent paradox is important for interpreting the risk program.
- **Dataset evidence**: GSK3B risk-associated (FDR=1.16×10⁻⁹); WNT7B also risk-associated (FDR=7.14×10⁻⁷).
- **External evidence**: GSK3B has dual roles: it phosphorylates β-catenin for degradation (tumor-suppressive) but also promotes NF-κB, cell-cycle, and metabolic signaling (potentially oncogenic). Its prognostic role in breast cancer is context-dependent.
- **Next step**: Determine whether GSK3B's risk association is mediated by non-Wnt substrates (e.g., cyclin D1 stability, NF-κB) using phospho-proteomic and pathway-interrogation approaches; test GSK3B inhibitors in models with high GSK3B expression.
- **Conclusion status**: Supported hypothesis (dual-role kinase); specific mechanism in this cohort is exploratory.

### Priority 5: ECM/Stromal Protective Signal
- **Classification**: Biomarker / composition check
- **Why**: The protective ECM cluster (COL17A1, LAMA2, OGN, OMD, RELN, ADAMTS8) is large and internally consistent but may reflect stromal or normal-adjacent content.
- **Dataset evidence**: 14+ protective ECM/stromal genes with FDR < 1.1×10⁻⁶.
- **External evidence**: Some ECM components are protective in breast cancer (e.g., laminins in differentiated epithelia), while others are pro-invasive. The direction here is consistently protective, which is notable.
- **Next step**: Spatial transcriptomics or laser-capture microdissection to localize expression; assess whether the protective signal reflects tumor purity, stromal content, or a differentiated tumor-cell phenotype. Validate in an independent cohort with matched clinical annotation.
- **Conclusion status**: Exploratory hypothesis; requires composition control before interpretation.

---

## 5. Evidence Grounding

| Evidence Category | Examples | Independence Assessment |
|---|---|---|
| **Direct input statistics** | All 100 genes with HR, P, FDR | Authoritative for this cohort; no external replication |
| **Pathway/ontology** | KEGG Cell cycle, Reactome mitotic/immune/ECM pathways, GO annotations | Contextual; derived from curated databases that may share underlying literature |
| **Protein interaction** | STRING: AURKA–TPX2, GSK3B–CTNNB1–AXIN1, CDC20–UBE2C–UBE2S | Contextual; interaction confidence scores reflect aggregated evidence; not independent of pathway databases |
| **Disease-association** | cBioPortal, ClinVar, OpenTargets records | Contextual; largely overlapping with published literature |
| **Expression/tissue** | GTEx, HPA, HumanBase | Contextual; tissue-specific expression supports plausibility but is not cohort replication |
| **Genetic/clinical** | ClinVar, GWAS | Contextual; mostly germline variant associations, not somatic prognostic evidence |
| **Drug/therapeutic** | ChEMBL, ClinicalTrials | Contextual; drug presence does not imply efficacy in breast cancer |
| **Published literature** | PubMed/Europe PMC records (e.g., PROS1 in breast cancer [37827342]; STIP1 pan-cancer [37488801]) | Contextual; may share underlying data with pathway/interaction databases |

**Key independence caveat**: Pathway databases (KEGG, Reactome, QuickGO), interaction databases (STRING, IntAct, OmniPath), and literature records are not independent of one another—they draw on overlapping primary publications. The direct cohort statistics are the only genuinely independent evidence in this analysis. **External statistical validation was not performed**; no independent-cohort statistic was supplied.

---

## 6. Limitations and Alternative Explanations

### Limitation 1: Cell-Composition Confounding
The protective immune and ECM signals may reflect immune-cell and stromal-cell content rather than tumor-cell-intrinsic biology. The risk-associated proliferation program is more likely tumor-cell-intrinsic, but even this could be influenced by tumor purity (higher purity → higher proliferation-gene signal).
**How to investigate**: Cell-type deconvolution (CIBERSORTx, xCell, MCP-counter), single-cell RNA-seq, or spatial transcriptomics; adjust survival models for estimated immune/stromal fractions.

### Limitation 2: Tumor Purity
Low-purity tumors would dilute tumor-intrinsic signals (proliferation) and inflate stromal/immune signals. The protective ECM cluster (COL17A1, LAMA2, OGN, OMD) is particularly susceptible to this artifact.
**How to investigate**: Estimate purity (e.g., ESTIMATE, ABSOLUTE) and include as covariate; validate in microdissected or single-cell data.

### Limitation 3: Disease Severity and Stage Confounding
The prognostic associations may partly reflect tumor stage, grade, or subtype distribution rather than independent molecular biology. Proliferation genes track with grade; immune infiltration tracks with subtype (higher in triple-negative and HER2+).
**How to investigate**: Multivariable Cox models adjusting for stage, grade, subtype, and treatment; stratified analysis by molecular subtype.

### Limitation 4: Treatment Exposure
The input data do not specify treatment. If patients received heterogeneous therapies (e.g., chemotherapy, endocrine therapy, HER2-targeted therapy), the survival associations could reflect treatment-response biology rather than intrinsic tumor aggressiveness. For example, high proliferation may predict chemotherapy sensitivity in some contexts, complicating the interpretation of risk.
**How to investigate**: Stratify by treatment arm or include treatment as a covariate; validate in cohorts with uniform treatment.

### Limitation 5: Association-versus-Causation Ambiguity
All genes are associated with OS, but the direction of causality is unknown. High expression of proliferation genes could drive poor survival (causal), or could be a marker of an underlying aggressive tumor phenotype. Similarly, immune-gene expression could reflect an effective anti-tumor response (causal) or merely mark a less-aggressive tumor subtype.
**How to investigate**: Functional perturbation studies (knockdown/overexpression), Mendelian randomization where applicable, and prospective validation.

### Additional Technical Note
The uploaded ledger contains 106 input rows for 100 unique genes (6 duplicated probes/rows), all with FDR ≤ 1.74×10⁻⁶. The extreme significance across all 100 genes is unusual and may reflect a large cohort, a strong underlying biological signal, or potential technical artifacts (e.g., overfitting in a multivariate model, or correlation among genes inflating apparent significance). The HR values are modest (0.79–1.26), so the clinical effect size per gene is small even though statistical significance is extreme.

---

## Summary

This breast cancer prognostic analysis reveals a clear and coherent biological architecture: **risk-associated genes are dominated by cell-cycle/mitotic and DNA-replication programs**, while **protective-associated genes reflect immune infiltration and certain ECM/differentiation programs**. The mitotic module (AURKA–TPX2, CDC20–UBE2C–UBE2S, PKMYT1) is the most robust risk signal and represents the most promising therapeutic direction, though drug efficacy remains unproven. The protective immune and ECM signals require cell-composition control before they can be interpreted as tumor-cell-intrinsic biology. External statistical validation in an independent cohort was not performed and is the single most important next step to establish generalizability of these findings.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=84, external claims checked=0, external mismatches=0, status=passed.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 100/100 selected items (records returned); cbioportal 100/100 selected items (records returned); chembl 52/100 selected items (records returned); civic 12/100 selected items (records returned); clinicaltrials 57/100 selected items (records returned); clinvar 100/100 selected items (records returned); ensembl 100/100 selected items (records returned); europepmc 990 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 98/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 99/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 99/100 selected items (partially returned; some queries failed); mygene 100/100 selected items (records returned); omnipath 65/100 selected items (records returned); opentargets 100/100 selected items (records returned); pubmed 791 articles / initial full-cohort RAG 100 queries + 3 current-round queries; some queries failed; quickgo 99/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 100/100 selected items (records returned)
Local databases: gutmgene 4/100 selected items (records returned); hmdb 31/100 selected items (records returned); string 100/100 selected items (records returned); trrust 40/100 selected items (records returned)
